Commonly prescribed medications from this drug class (GLP-1 receptor agonists) include semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)
As such, peptides have become intriguing candidates for studies related to the following: Obesity Diabetes management Sustainable weight management Despite these possibilities, several peptides are not approved for human consumption
Thankfully, research suggests that semaglutide may offer benefits in treating PCOS
By promoting healthy cellular turnover, it minimizes the chances of DNA damage and mutations that could lead to cancer
furthermore, DPP-4 inhibitors and GLP-1 receptor agonists entered the UK market in the same year